The biotechnology company Biogen has launched a website specifically looking at its Alzheimer’s drug candidate aducanumab. You can visit https://biogenalzheimers.com/ for updates on aducanumab and on Biogen’s plans for regulatory filing. If approved, aducanumab would become the first therapy to reduce the clinical decline of early Alzheimer’s disease.
